tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

ATYR Stock Latest News

Optimistic Outlook for aTyr Pharma’s Efzofitimod: High-Risk, High-Reward Potential in Phase 3 Trial
RatingsOptimistic Outlook for aTyr Pharma’s Efzofitimod: High-Risk, High-Reward Potential in Phase 3 Trial
18h ago
ATYR
aTyr Pharma Inc put volume heavy and directionally bearish
PremiumThe Fly
aTyr Pharma Inc put volume heavy and directionally bearish
4d ago
ATYR
aTyr Pharma management to meet with Cantor Fitzgerald
PremiumThe Fly
aTyr Pharma management to meet with Cantor Fitzgerald
4d ago
ATYR
High-Risk, High-Reward Opportunity in aTyr Pharma’s Efzofitimod Amid Upcoming Phase 3 Readout
PremiumRatings
High-Risk, High-Reward Opportunity in aTyr Pharma’s Efzofitimod Amid Upcoming Phase 3 Readout
10d ago
ATYR
Optimistic Buy Rating for aTyr Pharma Driven by Promising Phase 3 Progress of Efzofitimod in Pulmonary Sarcoidosis
PremiumRatings
Optimistic Buy Rating for aTyr Pharma Driven by Promising Phase 3 Progress of Efzofitimod in Pulmonary Sarcoidosis
11d ago
ATYR
aTyr Pharma announces last patient visit in Phase 3 EFZO-FIT study
PremiumThe FlyaTyr Pharma announces last patient visit in Phase 3 EFZO-FIT study
11d ago
ATYR
Promising Outlook for aTyr Pharma’s Efzofitimod Drives Buy Rating Amid Strong Market Potential
Premium
Ratings
Promising Outlook for aTyr Pharma’s Efzofitimod Drives Buy Rating Amid Strong Market Potential
23d ago
ATYR
Promising Outlook for aTyr Pharma: Buy Rating on Efzofitimod’s Potential in Phase 3 Trial
Premium
Ratings
Promising Outlook for aTyr Pharma: Buy Rating on Efzofitimod’s Potential in Phase 3 Trial
1M ago
ATYR
aTyr Pharma to be added to Russell 2000, Russell 3000 Indices
PremiumThe Fly
aTyr Pharma to be added to Russell 2000, Russell 3000 Indices
1M ago
ATYR
aTyr Pharma price target raised to $25 from $17 at Wells Fargo
PremiumThe Fly
aTyr Pharma price target raised to $25 from $17 at Wells Fargo
1M ago
ATYR
Promising Phase 2 Results for aTyr Pharma’s Efzofitimod in SSc-ILD Boost Investor Confidence
PremiumRatings
Promising Phase 2 Results for aTyr Pharma’s Efzofitimod in SSc-ILD Boost Investor Confidence
2M ago
ATYR
Positive Outlook on aTyr Pharma: Promising Phase 2 Results and Anticipation for Phase 3 Trials Justify Buy Rating
PremiumRatings
Positive Outlook on aTyr Pharma: Promising Phase 2 Results and Anticipation for Phase 3 Trials Justify Buy Rating
2M ago
ATYR
aTyr Pharma announces interim analysis from Phase 2 EFZO-CONNECT
PremiumThe FlyaTyr Pharma announces interim analysis from Phase 2 EFZO-CONNECT
2M ago
ATYR
aTyr Pharma management to meet with Piper Sandler
Premium
The Fly
aTyr Pharma management to meet with Piper Sandler
2M ago
ATYR
Buy Rating for aTyr Pharma: Confidence in EFZO-FIT Phase 3 Trial Success
Premium
Ratings
Buy Rating for aTyr Pharma: Confidence in EFZO-FIT Phase 3 Trial Success
2M ago
ATYR
aTyr Pharma presents three posters on efzofitimod at ATS 2025 Conference
PremiumThe Fly
aTyr Pharma presents three posters on efzofitimod at ATS 2025 Conference
2M ago
ATYR
aTyr Pharma’s Innovative Fibrosis Treatment and Promising Pipeline Garner Buy Rating
PremiumRatings
aTyr Pharma’s Innovative Fibrosis Treatment and Promising Pipeline Garner Buy Rating
2M ago
ATYR
aTyr Pharma advances ATYR0101 to IND candidate stage for pulmonary fibrosis
PremiumThe Fly
aTyr Pharma advances ATYR0101 to IND candidate stage for pulmonary fibrosis
3M ago
ATYR
Positive Outlook for aTyr Pharma: Buy Rating Reaffirmed Amid Promising EFZO-FIT Trial Prospects
PremiumRatings
Positive Outlook for aTyr Pharma: Buy Rating Reaffirmed Amid Promising EFZO-FIT Trial Prospects
3M ago
ATYR
Promising Outlook for aTyr Pharma: Phase 3 Study Progress and Potential Stock Upside
PremiumRatingsPromising Outlook for aTyr Pharma: Phase 3 Study Progress and Potential Stock Upside
3M ago
ATYR
Promising Clinical Advancements and Financial Stability Drive Buy Rating for aTyr Pharma
Premium
Ratings
Promising Clinical Advancements and Financial Stability Drive Buy Rating for aTyr Pharma
3M ago
ATYR
Promising Outlook for aTyr Pharma’s Efzofitimod and Strong Financial Position Reinforce Buy Rating
Premium
Ratings
Promising Outlook for aTyr Pharma’s Efzofitimod and Strong Financial Position Reinforce Buy Rating
3M ago
ATYR

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >